Immunotherapy for EGFR Mutated Lung Cancer
Published: 8 July 2024| Version 1 | DOI: 10.17632/3fjsc6y4n4.1
Contributor:
Ezzeldin IbrahimDescription
Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations face poor outcomes after progression on tyrosine kinase inhibitors (TKIs). The efficacy of immune checkpoint inhibitors (ICIs) combined with chemotherapy in these patients remains uncertain. Therefore, we performed this meta-analysis.
Files
Categories
Meta-Analysis